Unigestion Holding SA Cuts Position in Cencora, Inc. (NYSE:COR)

Unigestion Holding SA reduced its holdings in shares of Cencora, Inc. (NYSE:COR) by 14.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 127,820 shares of the company’s stock after selling 22,169 shares during the period. Cencora comprises 1.7% of Unigestion Holding SA’s investment portfolio, making the stock its 19th largest holding. Unigestion Holding SA’s holdings in Cencora were worth $28,719,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in COR. United Bank boosted its position in Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock worth $1,261,000 after purchasing an additional 225 shares during the period. Public Sector Pension Investment Board boosted its position in shares of Cencora by 53.2% in the third quarter. Public Sector Pension Investment Board now owns 6,908 shares of the company’s stock worth $1,555,000 after buying an additional 2,400 shares during the period. Arete Wealth Advisors LLC grew its stake in shares of Cencora by 4.9% in the third quarter. Arete Wealth Advisors LLC now owns 2,412 shares of the company’s stock valued at $541,000 after buying an additional 113 shares in the last quarter. Hilltop Holdings Inc. acquired a new stake in shares of Cencora in the third quarter valued at about $387,000. Finally, Integrated Wealth Concepts LLC raised its holdings in shares of Cencora by 116.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,969 shares of the company’s stock valued at $2,019,000 after buying an additional 4,831 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company’s stock, valued at $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,675 shares of company stock valued at $8,034,778 over the last 90 days. 10.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on COR shares. JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Price Performance

COR opened at $279.29 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The company has a 50-day moving average of $257.28 and a 200-day moving average of $242.70. The company has a market capitalization of $54.16 billion, a P/E ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.79%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.